GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Treatment Resistant Depression overview

Treatment-resistant depression (TRD) refers to a form of depression that does not adequately respond to standard treatments, such as antidepressant medications or psychotherapy, even after multiple trials of different therapies. It can be a challenging and distressing condition for individuals experiencing persistent depressive symptoms. Some common characteristics of treatment-resistant depression include inadequate response to antidepressants; persistent symptoms, which can include feelings of sadness, hopelessness, changes in sleep or appetite, fatigue, difficulty concentrating, and loss of interest in activities; and recurrent depressive episodes, wherein individuals experience multiple episodes of depression, each potentially resistant to standard treatments.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

G lobalDat a, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.